Department of Paediatric Research, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Anticancer Res. 2010 Oct;30(10):3879-87.
5-Fluorouracil (5-FU) is frequently used in cancer treatment. Previous studies with 5-FU suggest that proapoptotic protein BAX and tumor suppressor protein TP53 are central factors in this process. As the leukemic T cell line Jurkat E6 has mutations in both these genes, we investigated a possible activation of alternative death pathways following 5-FU treatment. Here we show that 5-FU triggers apoptosis in Jurkat cells in a dose-dependent manner. Death responses were only moderately attenuated in the presence of a general caspase inhibitor. However, flow cytometric analysis showed activation of caspase 3 and a slight increase in ROS generation in a time- and dose-dependent manner. Furthermore, we observed 5-FU induced PARP cleavage and notably, reduced expression of antiapoptotic MCL-1L associated with the appearance of proapoptotic MCL-1S. Our results demonstrate the activation of alternative death pathways following treatment with 5-FU, despite mutations in the TP53 and BAX genes.
5-氟尿嘧啶(5-FU)常用于癌症治疗。之前的 5-FU 研究表明,促凋亡蛋白 BAX 和肿瘤抑制蛋白 TP53 是这一过程的核心因素。由于白血病 T 细胞系 Jurkat E6 这两个基因都发生了突变,我们研究了 5-FU 治疗后是否可能激活替代的死亡途径。在这里,我们显示 5-FU 以剂量依赖的方式触发 Jurkat 细胞凋亡。在存在通用半胱天冬酶抑制剂的情况下,死亡反应仅适度减弱。然而,流式细胞术分析显示 caspase 3 的激活以及 ROS 生成呈时间和剂量依赖性的轻微增加。此外,我们观察到 5-FU 诱导 PARP 切割,值得注意的是,与促凋亡 MCL-1S 的出现相关联的抗凋亡 MCL-1L 的表达减少。我们的结果表明,尽管 TP53 和 BAX 基因发生突变,5-FU 治疗后仍会激活替代的死亡途径。